COVID-19-Associated Candidiasis (CAC): An Underestimated Complication in the Absence of Immunological Predispositions?
Year: 2020
Type: review
Abstract: The recent global pandemic of COVID-19 has predisposed a relatively high number of patients to acute respiratory distress syndrome (ARDS), which carries a risk of developing super-infections. Candida species are major constituents of the human mycobiome and the main cause of invasive fungal infections, with a high mortality rate. Invasive yeast infections (IYIs) are increasingly recognized as s complication of severe COVID-19. Despite the marked immune dysregulation in COVID-19, no prominent defects have been reported in immune cells that are critically required for immunity to Candida. This suggests that relevant clinical factors, including prolonged ICU stays, central venous catheters, and broad-spectrum antibiotic use, may be key factors causing COVID-19 patients to develop IYIs. Although data on the comparative performance of diagnostic tools are often lacking in COVID-19 patients, a combination of serological and molecular techniques may present a promising option for the identification of IYIs. Clinical awareness and screening are needed, as IYIs are difficult to diagnose, particularly in the setting of severe COVID-19. Echinocandins and azoles are the primary antifungal used to treat IYIs, yet the therapeutic failures exerted by multidrug-resistant Candida spp. such as C. auris and C. glabrata call for the development of new antifungal drugs with novel mechanisms of action.
Source: Journal of Fungi
DOI: 10.3390/jof6040211
Institutions: Hackensack Meridian Health, University of Minho, University of Pittsburgh, Mazandaran University of Medical Sciences, University of Bonn, Radboud University Nijmegen, Radboud University Medical Center, Radboud Institute for Molecular Life Sciences, Medical University of Graz, University of California San Diego
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Keywords: invasive fungal infections, Candida, severe COVID-19, superinfection, acute respiratory distress syndrome, immune dysregulation, central venous catheters, broad-spectrum antibiotics, ICU length of stay, serological diagnosis, molecular diagnosis, echinocandins, azoles, Candida auris, Candida glabrata, antifungal resistance, antifungal drug development
Open Access status: gold
Estimated APC paid: $1,479
Awards: G1255325603, G1516346500, G2179680425, G2440504136, Host directed medicine in invasive fungal infection, ICVS/3B’s - Laboratório Associado, Instituto de Ciências da Vida e da Saúde / Grupo de Investigação em Biomateriais, Biodegradaveis e Biomiméticos, G2838476969, G3326568298, ICVS/3B’s - Laboratório Associado, Instituto de Ciências da Vida e da Saúde / Grupo de Investigação em Biomateriais, Biodegradaveis e Biomiméticos, G4316116677, G434337789, Frontiers of technology for theranostics of cancer, metabolic and neurodegenerative diseases (FROnTHERA), G450822820, New avenues for the development of personalized medical interventions for neurological, oncologic and surgical disorders – “PersonalizedNOS”, G5132640529, G5454278309, G5955501538, G6116794534, G6122222817, G7584003722, G7685134749, G7731791180, Mecanismos moleculares e celulares de regulação da inflamação na sarcoidose, G8797326700, G96847669
OpenAlex ID: W3092528479
